Andrés Vilella Weisz

Alxerion Biotech Corp. engages in research and development in biotechnology. It provides services to drug delivery and discovery projects by integrating capabilities in Exosome-HTS technologies, in-house screening compounds libraries, animal models, gene therapy and nanocarrier technologies. The company was founded by Mercedes Balcells, Edelman R. Elazer and Javier Pedreño in 2017 and is headquartered in Cambridge, MA.

Alxerion Biotech Corp. engages in research and development in biotechnology. It provides services to drug delivery and discovery projects by integrating capabilities in Exosome-HTS technologies, in-house screening compounds libraries, animal models, gene therapy and nanocarrier technologies. The company was founded by Mercedes Balcells, Edelman R. Elazer and Javier Pedreño in 2017 and is headquartered in Cambridge, MA.

Alxerion Biotech Corp. engages in research and development in biotechnology. It provides services to drug delivery and discovery projects by integrating capabilities in Exosome-HTS technologies, in-house screening compounds libraries, animal models, gene therapy and nanocarrier technologies. The company was founded by Mercedes Balcells, Edelman R. Elazer and Javier Pedreño in 2017 and is headquartered in Cambridge, MA.

Alxerion Biotech Corp. engages in research and development in biotechnology. It provides services to drug delivery and discovery projects by integrating capabilities in Exosome-HTS technologies, in-house screening compounds libraries, animal models, gene therapy and nanocarrier technologies. The company was founded by Mercedes Balcells, Edelman R. Elazer and Javier Pedreño in 2017 and is headquartered in Cambridge, MA.